+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

COVID-19 Stem Cell Therapies Pipeline- Product Image

COVID-19 Stem Cell Therapies Pipeline

  • ID: 5021679
  • Report
  • April 2020
  • Region: Global
  • 100 Pages
  • IMAPAC
1 of 5
Featuring 22 Stem Cell Therapy Companies in APAC, EMEA and the Americas

FEATURED COMPANIES

  • Allovir
  • Athersys
  • Cynata Therapeutics
  • Kangstem Biotech
  • Mesoblast
  • Pharmicell
  • MORE

Complementing the slew of vaccines in development are the upcoming stem cell therapies, aimed at boosting patients’ immune systems and eliminating pathogens. The COVID-19 Stem Cell Therapies Pipeline report provides comprehensive data analysis of 22 organizations developing stem cell therapies for COVID-19 globally from the Americas, Europe, the Middle East and Africa (EMEA), and Asia-Pacific region (APAC).

Some report features include:

  • Lattice Biologics' collaboration with Alumina Partners for investments into accelerating phase 1 trials for its stem cell-based AminioBoost treatment of COVID-19.
  • Celularity's acceleration of its natural killer cell therapy to human clinical trial stage for COVID-19 patients, having gotten the go-ahead from the U.S. Food and Drug Administration.
  • Pharmicell's approval for the use of Cellgram-AKI to support COVID-19 emergency treatment.

The report covers the stem cell therapy market with a detailed review of their cell therapy research and development including the stages of production (pre-clinical, clinical and commercial). In addition, it pulls together insights from interviews and surveys with key opinion leaders. It seeks to holistically inform the community on the current status of COVID-19 stem cell therapy development and discover future opportunities for collaboration, technology transfer and co-development.


This report will be delivered within 3-5 business days.
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Allovir
  • Athersys
  • Cynata Therapeutics
  • Kangstem Biotech
  • Mesoblast
  • Pharmicell
  • MORE

Section 1

  • Report Scope
  • Data Pointers
  • Research Methodology

Section 2: COVID-19 Stem Cell Therapies Pipeline in the Americas

  • Company Overview
  • Product Portfolio
  • Certification
  • R&D Pipelines Analysis
  • Technology
  • Therapeutic Focus Areas
  • Partnerships And Collaborations
  • Interview
  • Financial Insights
  • Industry News & Updates
  • SWOT Analysis
  • References

Section 3: COVID-19 Stem Cell Therapies Pipeline in EMEA

  • Company Overview
  • Product Portfolio
  • Certification
  • R&D Pipelines Analysis
  • Technology
  • Therapeutic Focus Areas
  • Partnerships And Collaborations
  • Interview
  • Financial Insights
  • Industry News & Updates
  • Swot Analysis
  • References

Section 4: COVID-19 Stem Cell Therapies Pipeline in APAC

  • Company Overview
  • Product Portfolio
  • Certification
  • R&D Pipelines Analysis
  • Technology
  • Therapeutic Focus Areas
  • Partnerships And Collaborations
  • Interview
  • Financial Insights
  • Industry News & Updates
  • Swot Analysis
  • References

Section 5: Our Other Reports

  • Other Reports
  • Bibliography
  • Disclaimer
  • About the Author
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • Allovir
  • Athersys
  • Cynata Therapeutics
  • Kangstem Biotech
  • Mesoblast
  • Pharmicell
  • MORE
The COVID-19 Stem Cell Therapies Pipeline report provides comprehensive data analysis of stem cell therapies of 22 organizations tackling COVID-19 worldwide. Key regions covered are the Americas, Europe, the Middle East and Africa (EMEA), and Asia-Pacific region (APAC). The report covers the stem cell therapies market with detailed review of their research and development (R&D). In addition, it includes the stages of production (pre-clinical, clinical and commercial), country-wise analysis and ongoing partnerships. Moreover, it identifies opportunities for potential co-development opportunities. It features companies such as Cynata Therapeutics, Tianhe Stem Cell Biotechnologies, Pharmicell, SCM Lifescience, Anterogen, Kangstem Biotech, Mesoblast and many more.
Note: Product cover images may vary from those shown
5 of 5
  • Athersys
  • Vitro Biopharma
  • Celularity
  • Sanofi
  • Lattice Biologics
  • Allovir
  • Celltex Therapeutics Corporation
  • Pluristem Therapeutics
  • Immune System Regulation
  • Cynata Therapeutics
  • Tianhe Stem Cell Biotechnologies
  • Biostar Stem Cell Research Institute
  • Pharmicell
  • Scm Lifescience
  • Anterogen
  • Kangstem Biotech
  • Mesoblast
  • Reelabs
  • Peking University
  • Car-T (Shanghai) Biotechnology
  • Wuhan Hamilton Biotechnology
  • Shenzhen Ruipuxun Academy for Stem Cell & Regenerative Medicine
Note: Product cover images may vary from those shown
Adroll
adroll